ArticleJournal of clinical immunology2013
Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.
Article in Journal of clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Unmasking the 'rods and rings' antinuclear antibody pattern: a sign of hepatitis C treatment and a risk factor for cerebrovascular disease.Annals of medicine · 2025Article
- High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection.European journal of medical research · 2022Article
- The clinical value of indirect immunofluorescence for screening anti-rods and rings antibodies: A retrospective study of two centers in China.Frontiers in immunology · 2022Article
- A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation.Frontiers in immunology · 2022Article
- How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.Immunologic research · 2021Article
- Observational
- Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence.Gastroenterology and hepatology from bed to bench · 2021Article
- Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.Immunologic research · 2020Observational
- Long-term antiviral hepatitis C treatment associated with Rods and Ring Cytoplasmic antibodies.Medicine and pharmacy reports · 2019Article
- Primary biliary cholangitis with contemporary presence of anti-mithocondrial and anti-rods and rings autoantibodies: literature first case.Gastroenterology and hepatology from bed to bench · 2019Article
- Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.Immunologic research · 2018Article
- Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies.Clinical chemistry and laboratory medicine · 2018Article
- Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.Medical microbiology and immunology · 2017Article
- The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection.Hepatitis monthly · 2016Article
- Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.Auto- immunity highlights · 2016Article
- Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.World journal of gastroenterology · 2016Review
- Article
- Anti-rods and rings autoantibodies in a patient with hepatitis C virus infection.Annals of laboratory medicine · 2015Article
- Anti-rods/rings: a human model of drug-induced autoantibody generation.Frontiers in immunology · 2015Review
- Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures.Cell & bioscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAutoantibodies to cytoplasmic structures called rods and rings (RR) are primarily specific to patients with hepatitis C virus (HCV) infection treated with pegylated interferon-alpha/ribavirin (IFN/R). Our aim is to examine anti-RR antibodies specificity and correlation with the response to IFN/R therapy in two independent cohorts (US and Italy) of HCV patients.
methodsSera from the US cohort (n = 47) and the Italian cohort (n = 46) pre-selected for anti-RR antibodies were analyzed by immunofluorescence and radioimmunoprecipitation. The prevalence and titers of anti-RR were analyzed for correlation with the response to IFN/R therapy.
resultsIn the US cohort, anti-RR antibodies were more frequently non-responders to IFN/R (71 % vs 29 % responders). Titers in responder patients (n = 11) were ≤1:3200, whereas titers in non-responder patients (n = 27) reached 1:819,200 (p = 0.0016). In the Italian cohort, anti-RR titers ranged from 1:200 to >1:819,200 and only relapsers had the highest anti-RR titers. Radioimmunoprecipitation demonstrated that anti-RR autoantibodies were mainly anti-inosine monophosphate dehydrogenase 2 (IMPDH2) - 96 % in the Italian cohort vs. 53 % in the US cohort.
conclusionsIn the two cohorts analyzed, the anti-IMPDH2 response as a component of the anti-RR response is much more prominent in the Italian cohort. The reason for the difference between the US and Italian cohorts is unclear but it possibly illustrates the heterogeneity in response and the overall negative correlation between the production of these autoantibodies and response to IFN/R therapy. Patients with high titer anti-RR antibodies are either relapsers (Italian) or non-responders/relapsers (US).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.